Recent Advances in Molecular Biomarkers in Multiple Myeloma

home / insights / recent-advances-in-molecular-biomarkers-in-multiple-myeloma

Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.

EP. 1: Biomarkers in Multiple Myeloma (MM): Overview

August 10th 2022

Jonathan Kaufman, MD, provides an overview of multiple myeloma (MM) and reviews current biomarkers and molecular pathways commonly seen in MM.

EP. 2: Role of t(11;14) Translocation in Patients with MM

Shaji Kumar, MD;Jonathan L. Kaufman, MD

August 10th 2022

Dr Shaji Kumar explains the role of t(11;14) translocation in patients with multiple myeloma and discusses treatment options for this specific population.

EP. 3: Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM

Shaji Kumar, MD;Jonathan L. Kaufman, MD

August 18th 2022

Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.

EP. 4: Emerging Biomarkers in Multiple Myeloma

Shaji Kumar, MD;Jonathan L. Kaufman, MD

August 18th 2022

Shaji Kumar, MD, talks about new biomarkers that are being explored in patients with multiple myeloma.

EP. 5: Testing for Biomarkers in Multiple Myeloma

Shaji Kumar, MD;Jonathan L. Kaufman, MD

August 24th 2022

Two experts review strategies and barriers to overcome for biomarker testing in patients with multiple myeloma.

EP. 6: Future Perspectives in Biomarker Identification and Testing in MM

Shaji Kumar, MD;Jonathan L. Kaufman, MD

August 24th 2022

Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.